India's anti-obesity drug market saw a value growth slowdown in May 2026, with semaglutide revenues crawling to Rs 64 crore despite volumes rising to 190,000 units. Aggressive price cuts from 35 domestic generics have squeezed profit values, even as Eli Lilly's premium tirzepatide preserved its 63% market value dominance.
NEW DELHI, India — India's high-profile anti-obesity drug market experienced a noticeable deceleration in fiscal value growth during May 2026, following an initial multi-billion rupee surge triggered by the patent expiration of the blockbuster molecule semaglutide. While overall prescription volumes and unit consumption continued to climb across the country, intense competition among domestic pharmaceutical manufacturers has triggered a aggressive price war, compressing net profit margins and slowing down value expansion.
Data released by pharmaceutical market trackers shows that while total semaglutide unit volumes expanded from 170,000 units in April to 190,000 units in May, monthly revenues grew at a much slower rate, moving from 610 million Rupees (Rs 61 crore) to 640 million Rupees (Rs 64 crore). This stabilization stands in stark contrast to April, when the sudden introduction of low-cost domestic alternatives caused monthly semaglutide sales to nearly triple from their base line.
Market Consolidation and Shifting Brand Dominance
The post-patent landscape has seen a massive influx of domestic drugmakers attempting to capture market share. According to the latest retail data from PharmaTrac, a total of 35 generic brands have rushed into the anti-obesity drug market since the patent wall dropped on March 21, 2026. However, the intense competition has caused a highly uneven distribution of growth, with only seven brands posting positive sequential trajectory in May, while several early entrants experienced localized pullbacks.
Ahmedabad-based Torrent Pharmaceuticals, which commanded a dominant 38% share of the generic semaglutide race in April, reported a sequential contraction in its injectable segments. Its flagship injectable brand Semalix slid from 22,000 units to 20,000 units, while Sembolic dipped from 5,500 units to 4,700 units. Conversely, Torrent maintained solid upward momentum in its oral solid divisions, where Semalix and Sembolic tablets grew 9% and 32% respectively, combining for 59,000 units.
Taking advantage of this minor shift, Eris Lifesciences and Sun Pharmaceutical Industries improved their market standing significantly. Driven by a phased commercial launch, Eris Lifesciences' generic brand Sundae posted a 29% monthly jump to 27,000 units, making it the top-selling generic injectable by volume. Sun Pharma’s weight-loss specific brand Noveltreat and type-2 diabetes variant Sematrinity surged by 129% and 66% month-on-month, recording sales of 15,000 and 17,000 units.
Eli Lilly's Tirzepatide Retains Premium Value Dominance
While the generic semaglutide market fights through deep price reductions—with local variants retailing up to 80% cheaper than the original innovator drugs—the premium tier of India's anti-obesity drug market remains anchored by dual-acting GLP-1/GIP molecules. Eli Lilly’s tirzepatide, commercialized via direct imports under the brand name Mounjaro and co-marketed by Cipla under the brand Yurpeak, quickly returned to its baseline growth trends after a minor disruption during the initial generic semaglutide launch.
In May, tirzepatide formulations generated a massive 1.36 billion Rupees (Rs 136 crore) in net sales, moving 104,000 combined units. Despite being significantly more expensive than generic options, tirzepatide commands an absolute 63% share of India's total 19.06 billion Rupee (Rs 1,906 crore) moving annual turnover (MAT) for anti-obesity treatments. The innovator brand Mounjaro continues to rank as the highest-selling product by value across all metabolic therapeutic segments in the Indian sub-continent.
Heightened Regulatory Checks and Consumer Impact
For consumers, the rapid price deflation among generic formulations has dramatically increased affordability, broadening access beyond tier-1 urban pockets to middle-class demographics managing chronic obesity and type-2 diabetes. However, the sheer volume of cheap options has introduced distinct public health risks.
To curb unsupervised use, unauthorized retail distribution, and misleading digital lifestyle marketing, the Drug Controller General of India (DCGI) teamed up with regional state regulators to ramp up audits. Over the past few weeks, federal enforcement teams audited 49 distinct entities, targeting online e-pharmacy warehouses, commercial weight-loss clinics, and wholesale distribution grids to ensure these heavy metabolic agents are dispensed strictly under specialist prescription.
Official Sources Section
Market shares, volume trends, and revenue metrics are cited directly from the May 2026 monthly audit reports compiled by PharmaTrac and Pharmarack Technologies. Regulatory oversight guidelines, manufacturing notices, and enforcement audit counts are provided in accordance with the statutory advisories published by the Central Drugs Standard Control Organisation and the Government of India’s Press Information Bureau.
Quote Section
According to industry analysts reviewing the May pharmaceutical data:
"The initial volume explosion we witnessed in April was driven by stock building and aggressive pipeline filling across retail pharmacies. Now that over 35 brands are competing on price, the anti-obesity drug market value is experiencing a temporary stabilization. The massive volume growth shows the latent demand is there, but heavy discounting means companies must survive on tight margins or rely on oral tablets to sustain value."
Why It Matters
The financial stabilization of the generic semaglutide segment proves that India's healthcare landscape remains highly price-sensitive. For multinational innovators like Novo Nordisk and Eli Lilly, it highlights that while premium branding can protect high-end segments, mass-market volume in India belongs to low-cost domestic manufacturers. For local pharmaceutical companies, the May slowdown serves as a warning that running a race purely based on price cuts can quickly dilute overall segment profitability.
Key Facts at a Glance
Growth Slowdown: Semaglutide market value expansion slowed in May, rising marginally to Rs 64 crore from Rs 61 crore in April despite unit gains.
Volume Surge: Total monthly semaglutide consumption grew to 190,000 units, highlighting strong public demand.
Deep Price Cuts: Domestic generic semaglutide variants are retailing at prices up to 80% lower than original innovator imports.
Tirzepatide Rules Value: Eli Lilly's tirzepatide generated Rs 136 crore in May, commanding 63% of the total Rs 1,906 crore anti-obesity drug market.
Strict Government Audits: The DCGI audited 49 clinics and digital warehouses to block illegal, over-the-counter sales of weight-loss injectables.
FAQ Section
Why is the anti-obesity market value slowing down if more people are buying the drugs?
The slowdown in market value growth is caused by intense pricing competition. Because over 35 domestic generic brands entered the market simultaneously, they cut prices by up to 80% to win market share. As a result, even though the total number of boxes sold went up, the overall revenue generated stayed relatively flat.
What is the structural difference between Semaglutide and Tirzepatide?
Semaglutide is a single GLP-1 receptor agonist that mimics a natural hormone to regulate blood sugar and slow digestion to reduce appetite. Tirzepatide is a dual-acting molecule that targets both GLP-1 and GIP receptors, which clinical trials show generally yields a higher average percentage of body weight loss, allowing it to maintain a premium price tag.
Can any pharmacy sell these weight-loss injectables over the counter in India?
No. Following strict advisories issued by the Drug Controller General of India, these advanced GLP-1 agonist medications are strictly classified as schedule prescription drugs. They can only be legally dispensed by licensed pharmacies against valid prescriptions from endocrinologists, internal medicine specialists, or cardiologists.
Source: Central Drugs Standard Control Organisation (CDSCO), PharmaTrac IPM Performance Monthly Audit (May 2026), Government of India Press Information Bureau (PIB) Regulatory Disclosures.
